3 key advantages Moderna holds over Pfizer and AstraZeneca

They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.

| More on:
doctor holding covid-19 vaccine bottle

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Pfizer Inc (NYSE: PFE) appears to be likely to be the first drugmaker, along with its partner BioNTech (NASDAQ: BNTX), to win U.S. emergency use authorization (EUA) for a coronavirus vaccine. AstraZeneca (NASDAQ: AZN), with plans to produce up to 3 billion doses next year, might distribute more doses of its COVID-19 vaccine globally than any other company.

Do these leading positions mean that Moderna Inc (NASDAQ: MRNA) is playing second fiddle in the coronavirus vaccine race? Not for investors. Here are three key advantages that Moderna holds over both Pfizer and AstraZeneca.

1. No sharing required

Many of us were taught in kindergarten that it's good to share -- and our kindergarten teachers were right. In the biopharmaceutical world, though, sharing profits can translate to slower growth. Both Pfizer and AstraZeneca will share the rewards gained from their COVID vaccines.

Pfizer, as mentioned earlier, teamed up with BioNTech on coronavirus vaccine candidate BNT162b2. The big drugmaker forked over $72 million in cash to its partner, and bought a $113 million stake in the German biotech. BioNTech is also eligible to receive milestone payments of up to $563 million. The two companies didn't reveal how they're splitting revenue and profits on any sales of BNT162b2, but Pfizer certainly won't pocket all of the money the vaccine could make.

AstraZeneca partnered with the University of Oxford to develop and distribute experimental COVID-19 vaccine AZD1222. No financial details of the collaboration were announced. However, you can bet that Oxford will receive some level of royalties from any sales of the vaccine.

Meanwhile, Moderna has full ownership of COVID-19 vaccine candidate mRNA-1273, and doesn't have to share any potential revenue or profits from sales of the vaccine. Granted, Arbutus Biopharma owns the patent to lipid nanoparticle (LNP) technology used in the past by Moderna. However, Moderna has publicly stated that mRNA-1273 doesn't use any technology covered by Arbutus' patent.

2. Platform possibilities

If AstraZeneca wins regulatory approvals for AZD1222, the company has no other vaccine candidates that use similar technology waiting in the wings. It's the same story for Pfizer. However, good news for Moderna's mRNA-1273 could bode well for the rest of the biotech's pipeline.

Moderna hopes to leverage commercial success for mRNA-1273 into a full-blown mRNA (messenger RNA) platform. In addition to mRNA-1273, the company's pipeline currently includes 12 other mRNA vaccines and therapies in clinical testing. Moderna thinks it could expand that number to as many as 50 clinical-stage programs if the anticipated big bucks from mRNA-1273 begin to pour in.

Believe it or not, Moderna CEO Stephane Bancel thinks that the biotech could even become the biggest vaccine company in the world within the next four years. That view could be overly optimistic, but Moderna should grow at a much faster rate than AstraZeneca or Pfizer because of its platform possibilities.

3. Size

Last -- and least, in a literal sense -- is Moderna's size advantage over Pfizer and AstraZeneca. You might be thinking, "What size advantage?" After all, Pfizer's market cap tops $200 billion. AstraZeneca's market cap is close to $140 billion. Moderna is tiny in comparison, with a market cap in the ballpark of $50 billion. However, Moderna's smaller size is actually a big advantage.

It's not surprising at all that Moderna's stock gains so far in 2020 have been a lot better than the performances turned in by AstraZeneca and Pfizer. That's because positive developments for mRNA-1273 have moved the needle a lot more for Moderna than similar positive developments for AZD1222 and BNT162b2 have done for AstraZeneca and Pfizer, respectively.

Moderna still has a lot more room to run than either AstraZeneca or Pfizer. An additional $5 billion to $10 billion annually would be nice for these two big drugmakers, but wouldn't cause either of the two pharma stocks to skyrocket. On the other hand, that kind of revenue would likely light a fire beneath Moderna's share price.

We should soon know if mRNA-1273 will win EUA in the U.S. and regulatory approvals in other countries. If it does, Moderna stands to make billions of dollars in a short period. Its size, combined with its full ownership of its COVID vaccine and its platform possibilities, will almost certainly make Moderna a much bigger winner again in 2021 than AstraZeneca and Pfizer.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Keith Speights owns shares of Pfizer. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on International Stock News

A graphic illustration with the words NASDAQ atop a US city and currency
International Stock News

Why Big Tech became a huge wreck across the Nasdaq last night

Jerome Powell and his compadres shocked the market with an unexpected outlook.

Read more »

a man sits at a bar leaning sadly on his basketball wearing a US flag sticker on his cheekbone near a half drunk beer and looking despondent as though his basketball team has just lost a game.
International Stock News

The Dow Jones is on its longest losing streak in 46 years. What's going on?

The Dow is on a losing streak in the middle of a boom.

Read more »

A person leans over to whisper a secret to a colleague during a meeting.
International Stock News

Despite recent news, analysts still say Nvidia stock is a buy. Here's why

Last month, Nvidia was the most valuable company in the world.

Read more »

A young girl looks up and balances a pencil on her nose, while thinking about a decision she has to make.
International Stock News

After gaining 2,100%, is Nvidia stock done?

Nvidia has taken off as one of the key players in chips and services for artificial intelligence.

Read more »

A young couple in the back of a convertible car each raise a single arm in the air whilst enjoying a drive along the road.
International Stock News

Why Tesla stock just jumped again

Wedbush's Dan Ives thinks the stock will keep moving higher thanks to Tesla's self-driving technology.

Read more »

An older couple hold hands as they bounce happily high in the air.
International Stock News

Why the Alphabet share price just leapt higher

Investors seem to hope the Trump administration will be friendly to Alphabet and its big-tech peers.

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
International Stock News

Top Wall Street analyst calls Tesla stock a top pick. Is it a buy now?

Tesla shares have been on fire lately, rising more than 70% since the November 5 election.

Read more »

a couple clink champagne glasses on board a private aircraft with gourmet food plates set in front of them. They are wearing designer clothes and looking wealthy.
International Stock News

Billionaires love this US tech stock (Hint: It's not Nvidia)

Looking for the next big thing in tech investments? Several billionaire-owned hedge funds are heavily invested in one overlooked AI…

Read more »